SCHEMBL4991

SCHEMBL4991

OB(O)c1cccc(Cl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
PNMT P11086 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
NFKB1 P19838 1/20 0.40
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
ENPP2 Q13822 2/20 0.38
CYP2A6 P11509 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352520 1.00 TSHR (0.48) TSHRPNMTCYP1A2CYP3A4CYP2D6
SCHEMBL1116476 0.85 TSHR (0.48) TSHRPNMTCYP1A2CYP3A4CYP2D6
SCHEMBL16854674 0.82 TSHR (0.41) TSHRPNMTCYP1A2CYP3A4CYP2D6
SCHEMBL9571151 0.79 TSHR (0.43) TSHRPNMTCYP1A2CYP3A4CYP2D6
SCHEMBL29404220 0.79 TSHR (0.47) TSHRLMNAALDH1A1ENPP2
SCHEMBL4129 0.79 TSHR (0.47) TSHRLMNAALDH1A1ENPP2
SCHEMBL1125157 0.78 TSHR (0.52) TSHRCYP3A4NFKB1LMNAALDH1A1
SCHEMBL29954987 0.78 TSHR (0.52) TSHRCYP3A4NFKB1LMNAALDH1A1
SCHEMBL29957186 0.78 ALDH1A1 (0.40) TSHRCYP1A2ALDH1A1ENPP2CYP2A6
SCHEMBL1772196 0.78 ALDH1A1 (0.48) TSHRCYP1A2CYP3A4LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
WO-2024016826-A1 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF 杭州市第七人民医院 2024-01-25 WO claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
US-11793220-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2023-10-24 US claimed
CN-116916755-A Materials and methods for extending the shelf life of food products JP实验室公司 2023-10-20 CN claimed
CN-115232090-A 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof 杭州市第七人民医院 2022-10-25 CN claimed
US-20220264914-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-08-25 US claimed
EP-3024836-A1 IMPROVED PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES Bayer CropScience Aktiengesellschaft (DE) 2016-06-01 EP claimed
WO-2015011032-A1 IMPROVED PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES BAYER CROPSCIENCE AG (DE) 2015-01-29 WO claimed
US-8921299-B2 Detergents having acceptable color THE PROCTER & GAMBLE COMPANY (US) 2014-12-30 US claimed
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-7037905-B2 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2006-05-02 US claimed
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2004-03-18 US claimed
WO-2003105860-A1 PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF NOVO NORDISK A/S (DK) 2003-12-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof LIPE, CEL, LIPA TSHR 315/4885PNMT 3942/4885CYP1A2 781/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH TSHR 411/4885PNMT 715/4885CYP1A2 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.